Perioperative durvalumab has “the potential to transform the standard of care” for patients with muscle-invasive bladder ...

Adjuvant durvalumab did not improve disease-free survival in patients with early-stage non-small cell lung cancer in the phase 3 BR.31 trial.

NKTR-255 in combination with durvalumab following chemoradiation was well-tolerated in patients with non–small cell lung ...

The top stories in non-small cell lung cancer (NSCLC) for 2024 included practice-changing results in EGFR-mutant disease, an ...

iLSTA: Phase 1b/2a randomized, single-blind, single-center, safety and pharmacodynamic trial in Australia evaluating certepetide in combination with the checkpoint inhibitor, durvalumab, plus SoC ...

The 22nd Annual Winter Lung Cancer Conference, January 31-February 2, 2025, will cover advances in NSCLC and SCLC treatment.

While presenting the Union Budget for 2024-25 in the Lok Sabha, Finance Minister Nirmala Sitharaman proposed to cut customs ...

In these patients, adding tremelimumab to durvalumab and chemotherapy resulted in higher overall response rates (42.9%) relative to patients who received durvalumab plus chemotherapy (30.2%) or ...

NPPA directs manufacturers to reduce MRP of anti-cancer drugs following government's tax exemptions and duty reductions.

In a move aimed at providing relief to cancer patients, the National Pharmaceutical Pricing Authority (NPPA) has directed ...

New Delhi- The government has asked the companies to reduce prices of three anti-cancer drugs to pass on the benefit of ...

Treatment arms included standard chemotherapy alone, chemotherapy plus programmed death ligand 1 (PD-L1) inhibitor durvalumab, and chemotherapy plus durvalumab and cytotoxic T-lymphocyte ...